1921
Volume 93, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

Despite substantial progress in the control of infection due to the widespread deployment of insecticide-treated bed nets and artemisinin combination therapies, malaria remains a prolific killer, with over half a million deaths estimated to have occurred in 2013 alone. Recent evidence of the development of resistance to treatments in both parasites and their mosquito vectors has underscored the need for a vaccine. Here, we use a mathematical model of the within-host dynamics of infection, fit to data from controlled human malaria infection clinical trials, to predict the efficacy of co-administering the two most promising subunit vaccines, RTS,S/AS01 and ChAd63-MVA ME-TRAP. We conclude that currently available technologies could be combined to induce very high levels of sterile efficacy, even in immune-naive individuals.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.14-0767
2015-12-09
2017-09-26
Loading full text...

Full text loading...

/deliver/fulltext/14761645/93/6/1254.html?itemId=/content/journals/10.4269/ajtmh.14-0767&mimeType=html&fmt=ahah

References

  1. World Health Organization, 2014. World Malaria Report 2014. Geneva, Switzerland: WHO.
  2. Griffin JT, Hollingsworth TD, Okell LC, Churcher TS, White M, Hinsley W, Bousema T, Drakeley CJ, Ferguson NM, Basáñez M-G, Ghani AC, , 2010. Reducing Plasmodium falciparum malaria transmission in Africa: a model-based evaluation of intervention strategies. PLoS Med 7: e1000324.[Crossref]
  3. Dondorp A, Nosten F, Yi P, , 2009. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 361: 455467.[Crossref]
  4. Schwartz L, Brown GV, Genton B, Moorthy VS, , 2012. A review of malaria vaccine clinical projects based on the WHO rainbow table. Malar J 11: 11.[Crossref]
  5. WHO, 2014. Malaria Vaccine Rainbow Tables. Available at: http://www.who.int/vaccine_research/links/Rainbow/en/index.html. Accessed January 6, 2015.
  6. The RTSS Clinical Trials Partnership, 2011. First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med 365: 18631875.[Crossref]
  7. The RTSS Clinical Trials Partnership, 2014. Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med 11: e1001685.[Crossref]
  8. The RTSS Clinical Trials Partnership, 2015. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386: 3145.[Crossref]
  9. White MT, Bejon P, Olotu A, Griffin JT, Riley EM, Kester KE, Ockenhouse CF, Ghani AC, , 2013. The relationship between RTS,S vaccine-induced antibodies, CD4+ T cell responses and protection against Plasmodium falciparum infection. PLoS One 8: e61395.[Crossref]
  10. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, Schwenk R, Nielsen RA, Debebe Z, Pinelis E, Juompan L, Williams J, Dowler M, Stewart VA, Wirtz RA, Dubois M, Lievens M, Cohen J, Ballou WR, Heppner DG, Jr, 2009. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 200: 337346.[Crossref]
  11. Ewer KJ, O'Hara GA, Duncan CJA, Collins KA, Sheehy SH, Reyes-Sandoval A, Goodman AL, Edwards NJ, Elias SC, Halstead FD, Longley RJ, Rowland R, Poulton ID, Draper SJ, Blagborough AM, Berrie E, Moyle S, Williams N, Siani L, Folgori A, Colloca S, Sinden RE, Lawrie AM, Cortese R, Gilbert SC, Nicosia A, Hill AVS, , 2013. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 4: 2836.[Crossref]
  12. Bejon P, Andrews L, Andersen RF, Dunachie S, Webster D, Walther M, Gilbert SC, Peto T, Hill AVS, , 2005. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J Infect Dis 191: 619626.[Crossref]
  13. Ndungu FM, Mwacharo J, Kimani D, Kai O, Moris P, Jongert E, Vekemans J, Olotu A, Bejon P, , 2012. A statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS,S/AS01E. PLoS One 7: e52870.[Crossref]
  14. Duffy P, Kaslow D, , 1997. A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines. Infect Immun 65: 11091113.
  15. Hill AVS, , 2006. Pre-erythrocytic malaria vaccines: towards greater efficacy. Nat Rev Immunol 6: 2132.[Crossref]
  16. Hutchings CL, Birkett AJ, Moore AC, Hill AVS, , 2007. Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge. Infect Immun 75: 58195826.[Crossref]
  17. Moore AC, Hutchings CL, , 2007. Combination vaccines: synergistic simultaneous induction of antibody and T-cell immunity. Expert Rev Vaccines 6: 111121.[Crossref]
  18. White MT, Smith DL, , 2013. Synergism from combinations of infection-blocking malaria vaccines. Malar J 12: 280.[Crossref]
  19. Medica DL, Sinnis P, , 2005. Quantitative dynamics of Plasmodium yoelii sporozoite transmission by infected anopheline mosquitoes. Infect Immun 73: 43634369.[Crossref]
  20. Lyke KE, Laurens M, Adams M, Billingsley PF, Richman A, Loyevsky M, Chakravarty S, Plowe CV, Sim BKL, Edelman R, Hoffman SL, , 2010. Plasmodium falciparum malaria challenge by the bite of aseptic Anopheles stephensi mosquitoes: results of a randomized infectivity trial. PLoS One 5: e13490.[Crossref]
  21. Lourenço J, Recker M, , 2014. The 2012 Madeira Dengue Outbreak: epidemiological determinants and future epidemic potential. PLoS Negl Trop Dis 8: e3083.[Crossref]
  22. Andrews L, Andersen RF, Webster D, Dunachie S, Walther RM, Bejon P, Hunt-Cooke A, Bergson G, Sanderson F, Hill AV, Gilbert SC, , 2005. Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. Am J Trop Med Hyg 73: 191198.
  23. Guerin P, Olliaro P, Nosten F, , 2002. Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis 2: 564573.[Crossref]
  24. Hodgson SH, Ewer KJ, Bliss CM, Edwards NJ, Rampling T, Anagnostou NA, de Barra E, Havelock T, Bowyer G, Poulton ID, de Cassan S, Longley R, Illingworth JJ, Douglas AD, Mange PB, Collins KA, Roberts R, Gerry S, Berrie E, Moyle S, Colloca S, Cortese R, Sinden RE, Gilbert SC, Bejon P, Lawrie AM, Nicosia A, Faust SN, Hill AVS, , 2014. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J Infect Dis 211: 10761086.[Crossref]
  25. Ogwang C, Kimani D, Edwards NJ, Roberts R, Mwacharo J, Bowyer G, Bliss C, Hodgson SH, Njuguna P, Viebig NK, Nicosia A, Gitau E, Douglas S, Illingworth J, Marsh K, Lawrie A, Imoukhuede EB, Ewer K, Urban BC, Hill AVS, , 2015. Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults. Sci Transl Med 7: 110.[Crossref]
  26. Anderson RM, May RM, , 1991. Infectious Diseases of Humans: Dynamics and Control. Oxford, UK: Oxford University Press.
  27. Smith DL, McKenzie FE, Snow RW, Hay SI, , 2007. Revisiting the basic reproductive number for malaria and its implications for malaria control. PLoS Biol 5: e42.[Crossref]
  28. Gupta S, Trenholme K, Anderson RM, Day KP, , 1994. Antigenic diversity and the transmission dynamics of Plasmodium falciparum . Science 263: 961963.[Crossref]
  29. Artzy-Randrup Y, Dobson AP, Pascual M, , 2015. Synergistic and antagonistic interactions between bednets and vaccines in the control of malaria. Proc Natl Acad Sci USA 112: 30143019.[Crossref]
  30. Lynch PA, Grimm U, Thomas MB, Read AF, , 2012. Prospective malaria control using entomopathogenic fungi: comparative evaluation of impact on transmission and selection for resistance. Malar J 11: 383.[Crossref]
  31. Sturm A, Amino R, van de Sand C, Regen T, Retzlaff S, Rennenberg A, Krueger A, Pollok J-M, Menard R, Heussler VT, , 2006. Manipulation of host hepatocytes by the malaria parasite for delivery into liver sinusoids. Science 313: 12871290.[Crossref]
  32. Viriyavejakul P, Khachonsaksumet V, Punsawad C, , 2014. Liver changes in severe Plasmodium falciparum malaria: histopathology, apoptosis and nuclear factor kappa B expression. Malar J 13: 106.[Crossref]
  33. Roestenberg M, O'Hara GA, Duncan CJA, Epstein JE, Edwards NJ, Scholzen A, van der Ven AJAM, Hermsen CC, Hill AVS, Sauerwein RW, , 2012. Comparison of clinical and parasitological data from controlled human malaria infection trials. PLoS One 7: e38434.[Crossref]
  34. Baer K, Klotz C, Kappe SHI, Schnieder T, Frevert U, , 2007. Release of hepatic Plasmodium yoelii merozoites into the pulmonary microvasculature. PLoS Pathog 3: e171.[Crossref]
  35. Silvie O, Franetich JF, Charrin S, Mueller MS, Siau A, Bodescot M, Rubinstein E, Hannoun L, Charoenvit Y, Kocken CH, Thomas AW, Van Gemert GJ, Sauerwein RW, Blackman MJ, Anders RF, Pluschke G, Mazier D, , 2004. A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J Biol Chem 279: 94909496.[Crossref]
  36. Chuang I, Sedegah M, Cicatelli S, Spring M, Polhemus M, Tamminga C, Patterson N, Guerrero M, Bennett JW, McGrath S, Ganeshan H, Belmonte M, Farooq F, Abot E, Banania JG, Huang J, Newcomer R, Rein L, Litilit D, Richie NO, Wood C, Murphy J, Sauerwein R, Hermsen CC, McCoy AJ, Kamau E, Cummings J, Komisar J, Sutamihardja A, Shi M, Epstein JE, Maiolatesi S, Tosh D, Limbach K, Angov E, Bergmann-Leitner E, Bruder JT, Doolan DL, King CR, Carucci D, Dutta S, Soisson L, Diggs C, Hollingdale MR, Ockenhouse CF, Richie TL, , 2013. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One 8: e55571.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.14-0767
Loading
/content/journals/10.4269/ajtmh.14-0767
Loading

Data & Media loading...

Supplementary Data

Supplementary PDF

  • Received : 01 Dec 2014
  • Accepted : 06 Aug 2015

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error